COMPANY PROFILE

Wonjin Biotechnology

Explore full profile

Creating new medicines to treat complex and chronic diseases

Suwon, South KoreaFounded 2016Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Wonjin Biotechnology

Onegene Biotechnology is at the forefront of developing multi-target therapeutics aimed at addressing complex diseases. The company focuses on creating drugs that modulate multiple signals within the disease microenvironment, offering a comprehensive approach to treatment. Onegene's core technology involves enzyme-mediated protein-protein conjugation, which enhances the efficacy of their therapeutic solutions. The company primarily serves patients with chronic inflammation and advanced liver fibrosis, providing innovative treatments that activate the immune system within tumor microenvironments. Operating within the biotech sector, Onegene engages with key industry stakeholders, including firms, investors, and service providers, to drive innovation and bring their multi-modality drugs to market. Revenue is generated through the development and commercialization of these advanced therapeutics, positioning Onegene as a significant player in the biotech industry.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Suwon, South Korea
Employees: 21
Open positions: None listed
Dealroom signal: 29.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
OtherOther financing	May 2022	$0	—	STIC Ventures	↗
SERIES A✓Equity / VC	Feb 2021	$13M	$51M	UTC Investment · Korea Omega Investment · Premier Partners · SJ Investment Partners	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Wonjin Biotechnology website traffic

Latest recorded traffic for Wonjin Biotechnology is 360 monthly website visits, down 56.6% over the last three months. Wonjin Biotechnology's team declined 8.7% over the past year.

Latest monthly visits360 3-month web change-56.6% 1-year team growth-8.7%

Monthly website visitsApr 2021–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EBEntact BioA preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins	Watertown, United States	Operational	20	$121M	$405M
GTGluBio TherapeuticsEngages in molecular glue-targeted protein degradation drug discovery	China	Operational
CECellshootSearching for drug discovery target molecules and create groundbreaking new drug candidates	Tokyo, Japan	Operational
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational
ATAukera TherapeuticsBiotech company that develops novel therapeutics for patients suffering from mTOR protein related diseases	Basel, Switzerland	Operational
RPRefoxy PharmaRefoxy is a Pharmaceutical company discovering medicines to treat age-related diseases and extend the years of healthy living	Cologne, Germany	Operational
CTCimeio TherapeuticsDeveloping Shielded-Cell & Drug Pairs to increase cure rates for patients with hematologic malignancies, genetic and autoimmune diseases	Cambridge, United States	Operational
BTBAKX TherapeuticsWe create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations	Kingston, United States	Closed